A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).

Trial Details

NCT ID
NCT07258407
Phase
PHASE1 / PHASE2
Sponsor
T.O.A.D. Oncology SA
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • TD001
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Bordeaux, France|44.84124,-0.58046
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • Patient must fully understand the study requirements and voluntarily sign informed consent.
  • PSMA-expressing metastatic CRPC with documented progression based on serum PSA, RECIST 1.1 with PCWG3, and/or bone disease.
  • At least one measurable metastatic lesion per RECIST 1.1.
  • Adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →